Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAFV600 mutations

Publisher： John Wiley & Sons Inc

E-ISSN： 1346-8138|42|7|661-666

ISSN： 0385-2407

Source： THE JOURNAL OF DERMATOLOGY, Vol.42, Iss.7, 2015-07, pp. : 661-666

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 219-225

Karger

Access to resources Recommend Favorite

Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 307-313

Karger

Access to resources Recommend Favorite

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 694-700

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAFV600E mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 2, 2015-07 ,pp. : 282-285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1024-1031

John Wiley & Sons Inc

Access to resources Recommend Favorite